Role of mathematical modeling in protocol formulation in cancer chemotherapy.
The origin of drug resistance is discussed and the spontaneous mutation model is presented. The general implications of this model for the use of chemotherapy are considered and are found to agree with the broad range of experience from treating human malignancy. The large amount of information required to use this model to create detailed protocols does not permit its utilization at present, but it is hoped that such information will become available in the future.
A J
AJ
Coldman
J H
JH
Goldie
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D008466:Mechlorethamine / Q000627:therapeutic use; D008954:Models, Biological; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014747:Vinblastine; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone